Leaders in Pharmaceutical Business Intelligence (LPBI) Group

INACTIVE, 2/21/2016 – Rosalind Codrington, PhD — Inventor of Biologics and Diagnostics

Roles at GDE: LPBI & M3DP

EAW Status Changed to Inactive on 2/19/2016

• Inventor of Biologics and Diagnostics
• Expert, Author, Writer

1. CANCER BIOLOGY & Innovations in Cancer Therapy
2. Nanotechnology for Drug Delivery
3. Cell Biology, Signaling & Cell Circuits

• Developer of Intellectual Property on Medical 3D BioPrinting: R&D Biologics, Genomics and Tissue Engineering

Rosalind Codrington, PhD

 07795140423

r.codrington@abeterno.com

BIO

10+ years experience as a molecular biologist in the field of antibody fragments, cell-based assays, protein production and purification and more recently in nanoparticles. I have mostly worked with screening methods to discover new antibody fragments against known oncogenes including fusion proteins resulting from chromosomal translocations. I have also worked with animal models with the aim to study the biology of leukaemias and ultimately test the efficacy of antibody fragments as potential therapeutic molecules. Following my postdoctoral fellowships I moved into the private sector where I worked as a senior scientist to validate novel tumour markers on prostate cancer stem cells. I then co-founded ABeterno Ltd, to develop a ground breaking new technology to be able to extract, purify and trace live cells with nanoparticles using intracellular proteins. I am currently involved as well in an exciting new website project designed to promote freelance scientists, the Cambridge science network http://cambridgesciencenetwork.com

CAREER HISTORY

 

Cambridge Science Network Ltd, Cambridge. July 2015-current

Co-founder

http://cambridgesciencenetwork.com

A website designed to put in touch freelance scientists with companies and laboratory spaces to rent. This is a place, which will enable freelance scientists and companies showcase their skills and services and put them in touch with business leaders, thereby promoting their businesses.

 

ABeterno Ltd, Cambridge. Sept 2011–current

Scientific founder and CSO

I developed a novel cell isolation technology that makes use of magnetic nanoparticles to purify live cells using intracellular proteins. I set-up ABeterno Ltd to further develop the proof of concept. The project is an interface between molecular biology, cell biology, and chemistry. I have been involved in all of the operations including business development, project planning and hiring since the company set up.

Pro-cure Therapeutics Ltd, York. Nov 2010-July 2011

Senior Research Scientist

I had direct reporting responsibility to the senior management team, and I managed several projects in target validation for prostate cancer. I maintained several prostate cancer cell lines and performed knockout studies with siRNA and other cell based assays to validate the targets. Extracted and maintained primary prostate cancer initiating stem cells from patient biopsies.

 

University of Surrey, Guildford. Feb 2010–July 2010

Postdoctoral scientist

In this role I studied the role of oxidative stress in artherosclerotic lessions. During this time I was responsible for a PhD student and for developing a protocol to culture primary cells from carotid artery samples from mice.

 

University of Leeds, Department of Experimental Therapeutics Jan 2007– Jan 2010

Postdoctoral Research Fellow

I managed several projects mainly in the analysis and elucidation of the molecular pathways by which certain genes initiate leukaemias in vivo. I also worked on the generation of therapeutic antibody fragments against leukaemic targets using yeast two hybrid selection methods.

 

University of Cambridge, Department of Chemistry Jun 2005–Dec 2006

Postdoctoral Research Fellow

This project was an interface between molecular biology and biophysics. I worked on the telomerase complex to elucidate the stoichiometry of the complex at the single molecule level using single molecule fluorescence coincidence microscopy.

Royal Free Hospital, UCL, London, Sept 1998–Dec 2000

Research Assistant

I analysed patient biopsies with leukaemias to study the correlation between the incidence of alternative spliced forms with minimal residual disease.

EDUCATION

• PhD at MRC-LMB, University of Cambridge; Molecular Biology Jan 2001–Dec 2004

• Msc in Biomedical Sciences, University of Kingston, 1997-1998
• Bsc in Biochemistry, Queen Mary College, University of London, 1993–1997

INTERESTS

iking, swimming and playing the accordion. I am fluent in spoken and written Spanish and have basic knowledge in French and German.

 

PATENTS

WO2013/038158: Rosalind Codrington, ABeterno Ltd. Intracellular Cell Selection

WO2014/167282: Rosalind Codrington, ABeterno Ltd, In vivo cell imaging

PUBLICATIONS

1. McCormack MP, Young LF, Vasudevan S, de Graaf CA, Codrington R, Rabbitts TH, Jane SM, Curtis DJ. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science. 2010 Feb 12;327(5967):879-83
2. David Alves , Haitao Li , Rosalind Codrington , Angel Orte , Xiaojun Ren , David Klenerman, Shankar Balasubramanian. Single-molecule analysis of human telomerase monomer. Nat Chem Biol. 2008 May;4(5):287-9

3. Forster A, Pannell R, Drynan L, Cano F, Chan N, Codrington   R, Daser A, Lobato N, Metzler M, Nam CH, Rodriguez S, Tanaka T, Rabbitts T. Chromosomal translocation engineering to recapitulate primary events of human cancer. Cold Spring Harbor Symposia on Quantitative Biology 2005 Sep,70:275-282

4. Codrington R, Pannell R, Foster A, Drynan LF, Daser A, Lobato N, Metzler M, Rabbitts TH. A novel Cre-loxP-mediated chromosomal translocation model demonstrates the versatility of the Ewing’s sarcoma fusion protein. PLoS Biol. 2005 Aug;3(8):e242

5. Foster A, Pannell R, Drynan L, Codrington R, Daser A, Metzler M, lobato N, Rabbitts TH. The invertor knock-in conditional chromosomal translocation mimic. Nature Methods 2005 Jan; 2(1) 

6. Codrington R, O’Connor HE, Jalali GR, Carrara P, Papaioannou M, Hart SM, Hoffbrand AV, Potter M, Prentice HG, Harrison CJ, Foroni L. Analysis of ETV6/AML1 abnormalities in ALL: Incidence, alternative spliced forms and minimal residual disease Value. Br J Haematology

Dual Nationality: British and Swiss

Languages: French, Spanish, German